Thoracic cancers
Invited discussant abstracts 425PD, 426PD and 427PD
Date
19 Dec 2015Session
Thoracic cancersPresenters
Ross SooAuthors
R. SooAuthor affiliations
- Department Of Haematology-oncology, National University Health System, National University Cancer Institute, Singapore, 119228 - Singapore/SG
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
View the abstracts discussed:
- Clinical activity and safety of the EGFR mutant-specific inhibitor, BI1482694, in patients (pts) with T790M-positive NSCLC
- Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
- Prognostic significance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
Resources from the same session
1227 - Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)
Presenter: Leora Horn
Session: Thoracic cancers
Resources:
Abstract
965 - Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC
Presenter: Naiyer Rizvi
Session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
994 - Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) – results from ASCEND-2 and ASCEND-3
Presenter: Tony Mok
Session: Thoracic cancers
Resources:
Abstract
529 - Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced non-squamous non–small-cell lung cancer (NSCLC) with activating EGFR mutation (mt): JO25567 exploratory subgroup analysis
Presenter: Yukio Hosomi
Session: Thoracic cancers
Resources:
Abstract
Invited discussant abstracts 417O and 418O
Presenter: Johan Vansteenkiste
Session: Thoracic cancers
Resources:
Slides
Webcast
Invited discussant abstracts 419O and 420O
Presenter: Daniel Tan
Session: Thoracic cancers
Resources:
Slides
Webcast
1312 - Prospective monitoring of lung function tests with CO and NO diffusion during high dose thoracic radiotherapy for lung cancer: The CONORT study
Presenter: Francoise Mornex
Session: Thoracic cancers
Resources:
Abstract
870 - Local diagnostic practices for advanced non-small-cell lung cancer (NSCLC) in Chinese Patients: subset of the IGNITE study
Presenter: Baohui Han
Session: Thoracic cancers
Resources:
Abstract
804 - A prospective phase III study of three weekly versus weekly paclitaxel as second line therapy in advanced non small cell lung cancer
Presenter: Akhil Kapoor
Session: Thoracic cancers
Resources:
Abstract
702 - Individualization of docetaxel (DTX) treatment in East-Asian advanced non-small cell lung cancer (NSCLC) patients based on pharmacokinetically (PK)-guided dosing strategy: an open-label randomized clinical trial
Presenter: Yuxiang Ma
Session: Thoracic cancers
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.